Coherus' CHS-131 meets Phase IIb MS endpoint

Coherus BioSciences Inc. (NASDAQ:CHRS) said a 3 mg dose of CHS-131 met the primary endpoint of a Phase IIb study

Read the full 201 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE